AI Summary The GALAD score is a blood-based liver cancer risk score. It combines gender, age, and three tumor markers (AFP-L3, AFP, and DCP) to help doctors estimate the chance of hepatocellular carcinoma in people with chronic liver disease, especially cirrhosis. It does not diagnose cancer or replace ultrasound every 6 months. A higher score prompts closer follow-up. CT, MRI, or biopsy confirms a tumor, and treatment depends on tumor size and liver function.
Source: www.liverdirectory.com
Medically Reviewed.
The GALAD score is a liver cancer risk score. It combines blood tumor marker results with personal details to help doctors judge the chance of hepatocellular carcinoma (HCC), the most common type of liver cancer, in people with chronic liver disease.
It is not a diagnosis, and it does not replace ultrasound. This page explains what the score is for, how it fits with routine liver cancer checks, what a result can and cannot tell you, and what to ask your care team.
Liver Health AI Assistant
Ask Aimy
Aimy answers from LiverDirectory’s reviewed health information — helping patients make sense of liver-health terms, prepare for specialist visits, and explore what to look up next.
HCC RISK BLOOD TEST
The GALAD score is a liver cancer risk score. It belongs to a newer group of tools that combine blood-based tumor markers with clinical details, instead of relying on one blood test alone.
A tumor marker is a substance that can rise in the blood when a tumor is present. A score turns marker results and other details into one number that your care team can weigh.
The score focuses on hepatocellular carcinoma (HCC). People with cirrhosis face the highest risk. About 1–8% of people with cirrhosis develop HCC each year, depending on the cause of their liver disease.
Like other risk scores, GALAD does not look inside your liver and does not show a tumor. Your care team reads it alongside your ultrasound, your other blood tests, and your health history.
HCC RISK IN CHRONIC LIVER DISEASE
Risk tools only make sense for people whose liver disease already puts them at higher risk. Your doctor decides who needs them.
Cirrhosis from any cause is the strongest risk factor for HCC and is present in over 80% of people who develop it. Over ten years, the cumulative risk can reach 10–30% in high-risk groups, such as people with chronic viral hepatitis or advanced fibrosis. Learn how doctors grade cirrhosis on our Child-Pugh Score page.
Cirrhosis, chronic hepatitis B infection, and a prior history of HCC are all counted as high-risk situations. After a past HCC, guidance calls for checks every 4 months, using ultrasound plus tumor markers such as AFP, AFP-L3, or DCP.
HCC can arise in metabolic liver disease. Without cirrhosis, the chance of HCC in any one person is lower, which is why a biopsy is required to confirm a suspected tumor in that group. Read more on our Fatty Liver Disease page.
Routine surveillance is not recommended for people with Child-Turcotte-Pugh C cirrhosis who cannot have a transplant, or for people whose other serious illnesses limit life expectancy to less than 1–2 years.
AFP-L3, AFP, AND DCP
The name GALAD lists its parts: gender, age, AFP-L3, AFP, and DCP. A lab or your care team combines them into one number. You do not need to work it out yourself.
The score adds blood marker results to personal details. It does not add any new picture of your liver.
Each marker has its own page on this site. Read about them under Tumor Marker Blood Tests.
HCC SCREENING AND DIAGNOSIS
Each tool answers a different question. Doctors use them together.
| Tool | What it does | Role in liver cancer care |
|---|---|---|
| Liver ultrasound | Shows the liver with sound waves | Standard check every 6 months for people with cirrhosis |
| AFP blood test | Measures one tumor marker | Adding it to ultrasound finds more early cancers but also raises false alarms. It cannot diagnose HCC alone |
| AFP-L3 and DCP | Measure two more tumor markers | Guidelines pair them with ultrasound every 4 months after a past HCC |
| GALAD score | Combines marker results with age and sex into one risk number | Promising, but current guidance says it does not yet replace ultrasound for routine screening |
| Contrast-enhanced CT or MRI | Shows tumor patterns in the liver | Used to diagnose HCC in people at high risk, following LI-RADS criteria |
A risk score can point your team toward closer follow-up. Only imaging or a biopsy can confirm a tumor.
UNDERSTANDING YOUR GALAD RESULT
A GALAD result is one input to your care plan. It is not a verdict.
A lower score does not mean you can skip checks. People with cirrhosis still need regular ultrasound, because guidelines build surveillance on imaging.
A higher score is a reason to look closer. Your doctor may move up an ultrasound or order contrast-enhanced CT or MRI. It does not mean you have cancer.
Ask your care team which cutoff they use, how it changes your schedule, and whether it should be repeated. Keep your results so you can compare them over time.
AFTER YOUR RISK SCORE
Use your result to start a clearer conversation with your care team.
Early liver cancer often causes no symptoms, so checks on a schedule matter. Learn how ultrasound and other imaging are used on our HCC Imaging Surveillance page.
Ask which tumor markers were measured, which score your clinic uses, and when your next ultrasound is due. Ask who will call you with results.
If a tumor is found, treatment depends on its size, your liver function, and your overall health. Read about the cancer on our Hepatocellular Carcinoma page and the options on our Liver Cancer Therapies page.
A balanced, liver-friendly diet supports your liver, helps manage weight and blood sugar, and lowers the risk of other health problems during long-term follow-up.
Explore Liver DietThe Amsety Bar is a liver-friendly snack or meal replacement that can make it easier to eat well on busy days.
Shop Amsety Bars
Common Question
The GALAD score is used to estimate the chance of liver cancer (HCC) in people who already have chronic liver disease. It combines blood tumor marker results with age and sex into one number that your care team can weigh. The name lists its parts: gender, age, AFP-L3, AFP, and DCP. AFP, AFP-L3, and DCP are tumor markers, which are substances that can rise in the blood when a tumor is present. Doctors use them as clues, not proof. It is a risk tool, not a diagnostic test. It does not look inside your liver or show a tumor. Your care team reads it alongside your ultrasound, your other blood tests, and your health history. The goal is to find liver cancer early, when treatment can start in time. People with cirrhosis face the highest risk. About 1–8% develop HCC each year, depending on the cause of their liver disease. Over ten years, the cumulative risk can reach 10–30% in high-risk groups, such as people with chronic viral hepatitis or advanced fibrosis.
No. Blood biomarkers, including AFP alone or liquid biopsy, are not advised for diagnosing HCC because their accuracy is not high enough. AFP is no longer recommended as a diagnostic criterion for this reason. One reason is that AFP can also be raised by other liver conditions, such as cirrhosis and hepatitis. A high marker level does not prove a tumor, and a normal level does not rule one out. For people with cirrhosis or chronic hepatitis B, doctors diagnose HCC with specific imaging criteria called LI-RADS. The key findings on a contrast-enhanced multiphase CT or MRI are arterial phase hyperenhancement and washout. This means the area lights up early after contrast and then fades faster than the liver around it. A biopsy may be needed in some cases. For example, one is required to confirm a suspected tumor in people without cirrhosis. A risk score can prompt these tests, but it cannot replace them.
No. Current guidance says biomarkers other than AFP show promise but lack enough long-term data to replace ultrasound for routine screening. For people with cirrhosis, guidance calls for an abdominal ultrasound and an AFP blood test about every 6 months. Liver specialist guidance also prefers ultrasound with AFP over ultrasound alone. Adding AFP finds more early cancers, but it also raises more false alarms. Some people are hard to see well on ultrasound. In that case, guidance recommends contrast-enhanced CT or MRI instead. The schedule can change with your history. After a past HCC, guidance calls for checks every 4 months. After hepatitis C is cured with direct-acting antivirals, guidance describes ultrasound every 6 months for the first two years, with tumor marker tests at the doctor's discretion. If nothing is found, checks may move to every 12 months. Surveillance plans are individual, and doctors weigh the benefits against the harms. Ask your care team which schedule applies to you.
People with cirrhosis, chronic hepatitis B, or a past HCC may want to ask whether a biomarker-based score fits their care. Your doctor decides, and not every clinic offers it. These groups have a higher chance of HCC, so regular checks matter most for them. After a past HCC, guidance calls for checks every 4 months, using ultrasound plus tumor markers such as AFP, AFP-L3, or DCP. Other factors can raise risk too. After hepatitis C is cured with direct-acting antivirals, the most prominent risk factor for HCC is cirrhosis. Male sex, age 65 or older, a history of alcohol abuse, and diabetes also raise the odds. Surveillance is not advised for everyone. It is not recommended for people with Child-Turcotte-Pugh C cirrhosis who cannot have a transplant, or for people whose other serious illnesses limit life expectancy to less than 1–2 years. If you are unsure where you fit, ask your care team about your own risk and how often you should be checked.
No. A high score means your risk estimate is higher and your team may look more closely. It does not show a tumor. Your doctor may move up your next ultrasound or order a contrast-enhanced CT or MRI. Imaging or a biopsy is needed to confirm cancer. If a tumor is found, treatment depends on its size, your liver function, and your overall health. A lower score is not a reason to skip checks. People with cirrhosis still need regular ultrasound, because surveillance guidelines are built on imaging. Keep your results so you can compare them over time. Ask your team which cutoff they use, how the number changes your schedule, and who will call you with results.
Medical disclaimer: LiverDirectory provides educational information and a directory of providers. It does not provide medical advice, diagnosis, or treatment. Always consult a licensed physician regarding any medical condition.
